OUR PRODUCTS
United States
TARPEYO has received accelerated approval by the US Food and Drug Administration (FDA) for use in the US.
It is marketed in the US exclusively by Calliditas Therapeutics AB.
Europe
Kinpeygo® has been granted conditional marketing authorization by the European Commission (EC). It will be marketed in the European Economic Area (EEA), United Kingdom and Switzerland exclusively by STADA Arzneimittel AG.